We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

46 hedge funds and large institutions have $1.05M invested in BRAINSTORM CELL THERAPUTC in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $928K → $1.05M (+$125K)

0.16% less ownership

Funds ownership: 0.71% → 0.55% (-0.16%)

13% less funds holding

Funds holding: 53 → 46 (-7)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

52% less call options, than puts

Call options by funds: $23K | Put options by funds: $48K

Holders
46
Holders Change
-7
Holders Change %
-13.21%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
11
Closed
16
Calls
$23K
Puts
$48K
Net Calls
-$25K
Net Calls Change
+$714K

Top Buyers

Rank Fund Capital Flow
1
WCG
Weaver Consulting Group
California
+$20K
2
Morgan Stanley
Morgan Stanley
New York
+$14.5K
3
VF
Virtu Financial
New York
+$14.2K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.25K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$4.96K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$41K
2
GS
GTS Securities
New York
-$40.5K
3
Millennium Management
Millennium Management
New York
-$35.1K
4
SM
Sabby Management
Florida
-$27.3K
5
Two Sigma Investments
Two Sigma Investments
New York
-$15.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFG
26
Socha Financial Group
New York
$3.38K – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$3.27K – – –
HighTower Advisors
28
HighTower Advisors
Illinois
$3K -$45 -15 -2%
Osaic Holdings
29
Osaic Holdings
Arizona
$2.93K -$848 -283 -28%
CCMW
30
Cypress Capital Management (Wyoming)
Wyoming
$2.73K +$1.4K +467 +234%
IFAM
31
Institutional & Family Asset Management
Colorado
$1.64K – – –
SPIA
32
Steward Partners Investment Advisory
New York
$1.15K -$201 -67 -19%
BSB
33
Bangor Savings Bank
Maine
$1.09K – – –
UBS Group
34
UBS Group
Switzerland
$683 -$228 -76 -31%
EWA
35
EverSource Wealth Advisors
Alabama
$581 +$426 +142 New
VAG
36
VisionPoint Advisory Group
Texas
$531 – – –
AWM
37
Able Wealth Management
New Jersey
$524 +$384 +128 New
Bank of America
38
Bank of America
North Carolina
$287 +$9 +3 +4%
DJSG
39
D.J. St. Germain
Massachusetts
$137 – – –
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$99 – – –
WIM
41
Westside Investment Management
California
$54 – – –
Fidelity Investments
42
Fidelity Investments
Massachusetts
$35 +$24 +8 New
MSFP
43
Mark Sheptoff Financial Planning
Connecticut
$27 – – –
JP Morgan Chase
44
JP Morgan Chase
New York
$19 +$6 +2 +67%
Renaissance Technologies
45
Renaissance Technologies
New York
– -$41K -13,573 Closed
GS
46
GTS Securities
New York
– -$40.5K -13,515 Closed
Millennium Management
47
Millennium Management
New York
– -$35.1K -11,700 Closed
SM
48
Sabby Management
Florida
– -$27.3K -9,099 Closed
Two Sigma Investments
49
Two Sigma Investments
New York
– -$15.4K -5,145 Closed
T. Rowe Price Associates
50
T. Rowe Price Associates
Maryland
– -$9K -2,780 Closed
1
2
3

BCLI Hedge Fund Activity: Q4 2023 in Review

46 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2023, worth a combined $1.05M — up 13% from $928K a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of BCLI and 9 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Weaver Consulting Group, adding an estimated $20K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $41K sold.

  • 46 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2023, down from 53 in Q3 2023.
  • Funds reported $1.05M of BRAINSTORM CELL THERAPUTC stock for Q4 2023, up 13% quarter-over-quarter.
  • 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2023 and 16 closed out, a net change of -7 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2023 was Weaver Consulting Group, an estimated $20K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q4 2023 was Renaissance Technologies, an estimated $41K sold.

Based on aggregated 13F filings for Q4 2023.